Bausch + Lomb Advances Oral Dry AMD Treatment Development
MT newswire2026/10/06 21:2005:20 PM EDT, 10/06/2026 (MT Newswires) -- Bausch + Lomb (BLCO) said Tuesday it advanced clinical development of its investigational oral treatment for dry age-related macular degeneration after a constructive meeting with the US Food and Drug Administration. The regulatory agency was supportive, in principle, of the proposed initial study design to evaluate how the medicine behaves in the body and assess its safety, the company said. The eye health firm expects these initial results to support advancement into a phase 2 study for patients with dry AMD who have not yet developed advanced retinal damage and plans to start the clinical program in 2027, Bausch + Lomb said. The BL1243 program aims to address biological processes believed to contribute to retinal damage and leverages previous clinical experience involving roughly 2,100 people, the company added.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Crypto prices
More
